BO
BOVNF.US BioInvent International AB (publ)
- Market cap
- USD 18.4M
- P/E
- -
- P/B
- 0.90x
- ROE
- -239.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BOVNF.US undervalued?
Graham numberThe Graham number of BioInvent International AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioInvent International AB (publ) fundamental analysis
No fundamental analysis for BioInvent International AB (publ) yet.
BioInvent International AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tu…
Full company profileBioInvent International AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioInvent International AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.3M | 45.0M | 38.5M | 93.7M | 147M | 19.4M | 326M | 71.5M | 44.7M | 226M | 49.3M |
| Gross Profit | 70.3M | 42.1M | 38.5M | 93.7M | 147M | 19.4M | 326M | 71.5M | 44.7M | 226M | 49.3M |
| Operating Income | -62.9M | -101M | -123M | -138M | -75.5M | -278M | -50.9M | -370M | -471M | -351M | -485M |
| EBITDA | -61.6M | -97.6M | -118M | -127M | -64.0M | -263M | -27.1M | -313M | -452M | -331M | -467M |
| Net Income | -62.6M | -101M | -123M | -139M | -76.7M | -279M | -34.1M | -330M | -429M | -332M | -481M |
| EPS | -6.18 | -8.08 | -8.91 | -7.53 | -2.67 | -5.15 | -0.55 | -5.02 | -6.53 | -5.05 | -7.33 |
| Balance Sheet | |||||||||||
| Total Assets | 276M | 170M | 120M | 226M | 803M | 1.45B | 1.71B | 1.40B | 989M | 670M | 308M |
| Total Liabilities | 45.9M | 39.8M | 32.8M | 56.7M | 59.1M | 80.3M | 106M | 90.5M | 103M | 113M | 107M |
| Shareholders' Equity | 230M | 130M | 87.6M | 169M | 743M | 1.37B | 1.61B | 1.31B | 886M | 556M | 201M |
| Cash & Short-term Investments | 226M | 134M | 68.9M | 154M | 729M | 1.08B | 1.02B | 1.07B | 867M | 591M | 225M |
| Total Debt | - | - | - | 15.5M | 11.6M | 28.4M | 27.0M | 23.2M | 17.4M | 9.66M | 19.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -72.0M | -75.9M | -141M | -125M | -62.6M | -246M | -41.2M | -342M | -380M | -247M | -476M |
| Capital Expenditure | 5.32M | 16.5M | 3.85M | 3.84M | 6.70M | 13.3M | 12.4M | 13.3M | 10.0M | 7.24M | 1.90M |
| Free Cash Flow | -77.4M | -92.4M | -145M | -129M | -69.3M | -259M | -53.6M | -355M | -391M | -254M | -478M |
| Ratios | |||||||||||
| ROE | -27.2% | -77.2% | -140.6% | -82.1% | -10.3% | -20.4% | -2.1% | -25.2% | -48.5% | -59.7% | -239.6% |
| ROA | -22.7% | -59.1% | -102.3% | -61.5% | -9.6% | -19.3% | -2.0% | -23.6% | -43.4% | -49.6% | -156.3% |
| Net Profit Margin | -87.8% | -223.3% | -319.5% | -148.4% | -52.0% | -1,439.1% | -10.5% | -462.2% | -960.9% | -147.0% | -976.7% |
| Debt to Equity | - | - | - | 0.09x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioInvent International AB (publ) dividends
BioInvent International AB (publ) has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Dec 14, 2020.
Who owns BioInvent International AB (publ)
- Insiders 10.17%
- Institutions 57.68%
- Public & others 32.15%
- Shares outstanding 65.8M
- Free float 31.4M
BioInvent International AB (publ) company profile
- Company name
- BioInvent International AB (publ)
- Ticker
- BOVNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 107
- Fiscal year end
- December
- Address
- The Gamma Building, Lund, Sweden, 223 70
- Phone
- 46 4 62 86 85 50
- Website
- bioinvent.com
About BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
BioInvent International AB (publ) management
10- Dr. Martin Welschof Ph.D.President & CEO · born 1961
- Mr. Stefan Ericsson M.B.A.Chief Financial Officer · born 1963
- Mr. Kristoffer Rudenholm HanssonSenior Vice President of Technical Operations · born 1974
- Mr. Björn FrendéusChief Scientific Officer · born 1973
- Ms. Cecilia HofvanderVice President of Investor Relations · born 1967
- Dr. Andres McAllisterChief Medical Officer · born 1956
- Ms. Ingrid TeigeHead of Preclinical Research
- Ms. Sylvie RyckebuschChief Business Officer · born 1965
- Dr. Ingunn Munch LindvigSenior Vice President of Regulatory Affairs · born 1965
- Mr. Ashley R. RobinsonSenior VP of Strategy & Finance · born 1977